Arnold KA - Search Results

1

Disposition of oral and intravenous pravastatin in MRP2-deficient TR- rats.

Kivistö KT, Grisk O, Hofmann U, Meissner K, Möritz KU, Ritter C, Arnold KA, Lutjöohann D, von Bergmann K, Klöting I, Eichelbaum M, Kroemer HK. Kivistö KT, et al. Among authors: arnold ka. Drug Metab Dispos. 2005 Nov;33(11):1593-6. doi: 10.1124/dmd.105.006262. Epub 2005 Aug 17. Drug Metab Dispos. 2005. PMID: 16107564

2

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin.

Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lütjohann D, von Bergmann K, Eichelbaum M, Kivistö KT. Igel M, et al. Among authors: arnold ka. Clin Pharmacol Ther. 2006 May;79(5):419-26. doi: 10.1016/j.clpt.2006.01.010. Epub 2006 Apr 11. Clin Pharmacol Ther. 2006. PMID: 16678544 Clinical Trial.

3

A role for constitutive androstane receptor in the regulation of human intestinal MDR1 expression.

Burk O, Arnold KA, Geick A, Tegude H, Eichelbaum M. Burk O, et al. Among authors: arnold ka. Biol Chem. 2005 Jun;386(6):503-13. doi: 10.1515/BC.2005.060. Biol Chem. 2005. PMID: 16006237

4

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.

Niemi M, Arnold KA, Backman JT, Pasanen MK, Gödtel-Armbrust U, Wojnowski L, Zanger UM, Neuvonen PJ, Eichelbaum M, Kivistö KT, Lang T. Niemi M, et al. Among authors: arnold ka. Pharmacogenet Genomics. 2006 Nov;16(11):801-8. doi: 10.1097/01.fpc.0000230422.50962.91. Pharmacogenet Genomics. 2006. PMID: 17047488

5

Alternative splicing affects the function and tissue-specific expression of the human constitutive androstane receptor.

Arnold KA, Eichelbaum M, Burk O. Arnold KA, et al. Nucl Recept. 2004 Mar 25;2(1):1. doi: 10.1186/1478-1336-2-1. Nucl Recept. 2004. PMID: 15043764 Free PMC article.

6

Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.

Burk O, Arnold KA, Nussler AK, Schaeffeler E, Efimova E, Avery BA, Avery MA, Fromm MF, Eichelbaum M. Burk O, et al. Among authors: arnold ka. Mol Pharmacol. 2005 Jun;67(6):1954-65. doi: 10.1124/mol.104.009019. Epub 2005 Mar 10. Mol Pharmacol. 2005. PMID: 15761118

7

The rate of decline of diphenylhydantoin in human plasma.

Arnold K, Gerber N. Arnold K, et al. Clin Pharmacol Ther. 1970 Jan-Feb;11(1):121-34. doi: 10.1002/cpt1970111121. Clin Pharmacol Ther. 1970. PMID: 5410894 No abstract available.

8

The effect of diphenyl-piperazine compounds and other agents on diphenylhydantoin, zoxazolamine and hexobarbital metabolism.

Gerber N, Arnold K. Gerber N, et al. J Pharmacol Exp Ther. 1968 Nov;164(1):232-8. J Pharmacol Exp Ther. 1968. PMID: 4387047 No abstract available.

9

Studies on the metabolism of diphenylhydantoin in mice.

Gerber N, Arnold K. Gerber N, et al. J Pharmacol Exp Ther. 1969 May;167(1):77-90. J Pharmacol Exp Ther. 1969. PMID: 5772752 No abstract available.

10

CLDN1 knock out keratinocytes as a model to investigate multiple skin disorders.

Arnold KA, Moran MC, Shi H, van Vlijmen-Willems IMJJ, Rodijk-Olthuis D, Smits JPH, Brewer MG. Arnold KA, et al. Exp Dermatol. 2024 May;33(5):e15084. doi: 10.1111/exd.15084. Exp Dermatol. 2024. PMID: 38711223

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters